Phase 2a Study in Healthy Adult Participants Pre-treated With INNA-051 and Challenged With Influenza Virus
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 123
- 试验地点
- 1
- 主要终点
- Evaluate the antiviral effect of INNA-051 compared to placebo against influenza virus
研究概览
简要总结
This is a Phase 2, randomized, double-blind, placebo-controlled study of INNA-051 in healthy adults, administered prior to administration of an influenza challenge virus. This study will evaluate 2 active dose levels of INNA-051 and placebo.
详细描述
Healthy participants will be administered 2 doses on INNA-051 intra-nasally and subsequently administered influenza virus as a challenge. Participants will be quarantined for 8 days. Study assessments will be performed during this period and they will monitored for symptoms of influenza infection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Provide written informed consent
- •18 to 55 years (inclusive) at time of consent
- •In good health with no history, or current evidence, of clinically significant medical conditions, and no clinically significant test abnormalities that will interfere with participant safety
- •Agree to use highly effective contraception
排除标准
- •History of, or currently active, symptoms or signs suggestive of URT or lower respiratory tract (LRT) infection within 4 weeks prior to the first study visit
- •Any history or evidence of any other clinically significant or currently active systemic comorbidities including psychiatric disorders (includes participants with a history of depression and/or anxiety)
- •Participants who have smoked ≥10 pack years at any time
- •A total body weight ≤50 kg or body mass index (BMI) ≤18 kg/m2 or ≥35kg/m
- •Pregnant or breast feeding
- •Any significant abnormality altering the anatomy of the nose or nasopharynx that may interfere with the nasal assessments or viral challenge, clinically significant history of epistaxis, or any nasal or sinus surgery within 3 months of the first study visit
- •vaccinations within the 4 weeks prior to the planned date of first dosing with IMP (10 days for SARS-CoV-2 vaccines, 6 months for influenza vaccine), or during the study
- •Receipt of blood or blood products, or loss (including blood donations) of 470 mL or more of blood during the 3 months prior to dosing or planned in 3 months post.
- •Receipt of any investigational product within 3 months (or 5 half-lives of the investigational product used in the other study, whichever is greater) prior to first dose with IMP, or 3 IMPs within prior 12 months, or prior administration with a virus from the same virus family as the challenge virus, or prior participation in another respiratory viral challenge study in the preceding 3 months
- •Confirmed positive test for drugs of abuse or cotinine, history or presence of alcohol addiction, or excessive consumption of xanthine-containing substances
- •A forced expiratory volume in 1 second (FEV1) <80%
- •Positive HIV-1 or HIV-2 test, or positive test for hepatitis B or C
研究组 & 干预措施
INNA-051 arm 1
INNA-051 intranasal spray low dose administered once on each of Days -4 and -2 prior to viral challenge
干预措施: INNA-051 (Drug)
INNA-051 arm 2
NNA-051 intranasal spray high dose administered once on each of Days -4 and -2 prior to viral challenge
干预措施: INNA-051 (Drug)
Placebo
Placebo intranasal spray low dose administered once on each of Days -4 and -2 prior to viral challenge
干预措施: Placebo (Other)
结局指标
主要结局
Evaluate the antiviral effect of INNA-051 compared to placebo against influenza virus
时间窗: To Day 8
Change in total viral load area under the curve (AUC) measured by quantitative reverse transcriptase-polymerase chain reaction (qRT PCR) in treated participants vs. placebo participants.
次要结局
- To evaluate the antiviral effect of INNA-051 in reducing detectable virus levels when compared to placebo(To Day 8)
- To evaluate the antiviral effect of INNA-051 in reducing symptoms of influenza infection when compared to placebo(To Day 8)
- Incidence of treatment emergent adverse events(To Day 8)
- To evaluate the antiviral effect of INNA-051 in reducing viral load when compared to placebo(To Day 8)
- To evaluate the antiviral effect of INNA-051 in reducing incidence of infection when compared to placebo(To Day 8)